摘要
在欧洲和日本，政府对药品定价和补偿的持续性干预使以研究为基础的药品销售处于紧张状态。成功的创新型药品生产商都将它们的注意力从具有巨大潜在销售额——被称作“巨型炸弹”模型——的治疗领域转向关注开发治疗稀少疾病的药物。
Continued governmental control over the pricing and reimbursement of medicines is placing strain on the sales of research-based medicine in Europe and Japan. Successful innovative drug producers are shifting their attention away from large therapeutic areas with potentially vast sales volumes - the so-called ＂blockbuster＂ model - to focus on developing products to treat in niche areas such as rare diseases.
